Torrent Pharmaceuticals share price was up on December 5 after the company acquired three brands from Germany's Boehringer Ingelheim GmbH.
At 10:13am, Torrent Pharmaceuticals was quoting at Rs 3,365.80, up Rs 16.20, or 0.48 percent, on the BSE.
"... entered into an agreement to acquire brands Cospiaq (empagliflozin), Cospiaq Met (empagliflozin + metformin) and Xilingio (empagliflozin + linagliptin) from Boehringer Ingelheim International GmbH (BI)," company said in its release.
The acquisition is expected to be completed in March 2025.
Torrent has been marketing these brands since 2022 as part of an existing co-marketing agreement with Boehringer Ingelheim India.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor which is indicated for glycemic control in adults with type 2 diabetes mellitus.
Catch all the market action on our live blog
The company in the quarter ended September 2024 had posted 40 percent jump in its net profit at Rs 460 crore.
In the month of November, the company received an Establishment Inspection Report (EIR) from USFDA for its facility at Pithampur, Madhya Pradesh.
The share touched a 52-week high of Rs 3,589.95 and a 52-week low of Rs 2,025.00 on 10 October, 2024 and 13 December, 2023, respectively.
Currently, the stock is trading 6.24 percent below its 52-week high and 66.21 percent above its 52-week low.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
